Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

Hepatitis B-infected patients with longer telomeres more likely to develop HCC

Hepatitis B-infected patients with significantly longer telomeres—the caps on the end of chromosomes that protect our genetic data— were found to have an increased risk of getting liver cancer compared to those with shorter ones, according to findings presented by researchers at Jefferson's Kimmel Cancer Center at the American Association for Cancer Research (AACR) Annual Meeting 2012.

4 Apr 2012

CYP1B1 protein may be a potential target for intervention in head and neck cancer

Squamous cell carcinoma of the head and neck-which typically arises from thin, flat cells that line moist surfaces inside the mouth, nose and throat-is the sixth most common type of cancer worldwide, and it has a relatively low five-year survival rate and a high recurrence rate.

2 Apr 2012

Safe method for destroying cancer cells using death cap mushroom poison

The mere thought of an identification error sends a chill down the spine of any mushroom lover: The death cap mushroom (Amanita phalloides), which resembles the common white button mushroom, contains one of the most deadly poisons found in nature, α-amanitin.

2 Apr 2012

Targeting inflammatory pathways may lead to new therapies

Scientists at Fox Chase Cancer Center have uncovered more details about how defects in components of the machinery that makes new proteins can lead to blood and other cancers.

2 Apr 2012

Enrollment complete in Oncolytics REOLYSIN combination trial for head and neck cancers

Oncolytics Biotech Inc. announced today that it has completed enrollment in the first, 80 patient stage of its Phase III clinical trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers (REO 018).

2 Apr 2012

Clinical data for cabozantinib to be presented at ASCO annual meeting

Exelixis, Inc. announced today that its lead compound, cabozantinib, will be the subject of nine separate data presentations at the upcoming Annual Meeting of the American Society of Clinical Oncology.

2 Apr 2012

Metformin prevents primary liver cancer in animal models

Metformin, a drug widely used to treat Type II diabetes, may help to prevent primary liver cancer, researchers at the University of Maryland Marlene and Stewart Greenebaum Cancer Center report in the April 2012 issue of Cancer Prevention Research.

2 Apr 2012

Metformin may slow growth rate of prostate cancer in men

The use of metformin in men with prostate cancer before prostatectomy helped to reduce certain metabolic parameters and slow the growth rate of the cancer, according to the results of a phase II study.

2 Apr 2012

CT scans more effective than traditional lung cancer detection methods

A new study led by researchers at Mount Sinai School of Medicine indicates that CT scans are more effective than traditional lung cancer detection methods at identifying aggressive lung cancers in their most treatable stages.

31 Mar 2012

ImmunoGen commences IMGN901 Phase II evaluation for SCLC

ImmunoGen, Inc. today announced that it has initiated Phase II testing of its IMGN901 product candidate for first-line treatment of SCLC.

31 Mar 2012

Cancer cells grow and proliferate more robustly when exposed to human cells

New research from the Technion-Israel Institute of Technology Rappaport Faculty of Medicine and Research Institute and the Rambam Medical Center may lead to the development of new methods for controlling the growth of cancer, and perhaps lead to treatments that will transform cancer from a lethal disease to a chronic, manageable one, similar to AIDS.

30 Mar 2012

Papillary renal cell carcinoma patients face low tumour re-occurrence and cancer-related death rates

Patients with papillary renal cell carcinoma, the second most common kidney cancer subtype, face a low risk of tumour recurrence and cancer-related death after surgery. Those are the key findings of a multi-centre study of nearly 600 patients published in the April issue of the urology journal BJUI.

29 Mar 2012

Vaccination for HPV reduces risk of renewed disease

The vaccination against human papillomavirus (HPV) reduces the risk of a renewed HPV-associated illness in patients who have already had diseases as a consequence of an HPV infection.

29 Mar 2012

Study calls for re-examination of criteria used to prioritize liver transplant candidates

Patients with end-stage liver disease complicated by the most common type of liver cancer - hepatocellular carcinoma (HCC) - are less likely to die or become too sick for a transplant while waiting for a new liver than those with other complications of end-stage liver disease, according to new research from the Perelman School of Medicine at the University of Pennsylvania.

29 Mar 2012

Navidea announces data from Lymphoseek Phase 3 study on oral and squamous cell cancers

Navidea Biopharmaceuticals, Inc., a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Phase 3 clinical study investigating 99m-Tc-Tilmanocept in oral and squamous cell cancers (SCC) were presented as a poster presentation at the 65th Annual Cancer Symposium of the Society of Surgical Oncology (SSO) meeting held in Orlando, Florida, March 21-24, 2012.

29 Mar 2012

Lung cancers diagnosed in CT screening are similar to those found in clinical practice

Growth rates of lung cancers found by annual rounds of computed tomography (CT) screening are important for determining the usefulness and frequency of screening, as well as for determining the treatment.

28 Mar 2012

Nordion introduces new custom dose feature in Canada, Europe for TheraSphere

Nordion Inc., a leading provider of products and services for the prevention, diagnosis and treatment of disease, today launched a new custom dose feature in Europe and Canada for TheraSphere, Nordion's Y-90 microsphere treatment for liver cancer.

26 Mar 2012

RT after surgery could reduce chances of local DCIS recurrence by 50%

Radiotherapy treatment (RT) after surgery for ductal carcinoma in situ (DCIS) still has a major protective effect against recurrence more than 15 years later, according to the results of an international trial.

23 Mar 2012

HCC patients have reduced risk of waitlist mortality

New research shows increasing disparity in mortality among candidates with and without hepatocellular carcinoma (HCC) who are on the waiting list for liver transplantation. The study available in the April issue of Liver Transplantation, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases, found that liver cancer patients are less likely to die on the wait list than non-HCC candidates, prompting transplantation specialists to suggest a reevaluation of current allotment criteria for those with HCC.

23 Mar 2012

Women diagnosed with DCIS need clear communication guidelines

Women diagnosed with ductal carcinoma in situ (DCIS) need clear communication and tailored support to enable them to understand this complex breast condition, which has divided the medical profession when it comes to its perception and prognosis.

22 Mar 2012